VKTX vs. MDGL

Last updated Apr 2, 2026

Compare and contrast key facts about Viking Therapeutics, Inc. (VKTX) and Madrigal Pharmaceuticals, Inc. (MDGL).

Performance

VKTX vs. MDGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viking Therapeutics, Inc. (VKTX) and Madrigal Pharmaceuticals, Inc. (MDGL). The values are adjusted to include any dividend payments, if applicable.

VKTX vs. MDGL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VKTX Viking Therapeutics, Inc.	-6.31%	-12.57%	116.23%	97.98%	104.35%	-18.29%	-29.80%	4.84%	88.42%	241.18%
MDGL Madrigal Pharmaceuticals, Inc.	-9.02%	88.72%	33.36%	-20.28%	242.52%	-23.77%	22.02%	-19.17%	22.80%	516.04%

Fundamentals

Market Cap VKTX : $3.76B MDGL : $11.89B
EPS VKTX : -$3.19 MDGL : -$12.88
PB Ratio VKTX : 5.88 MDGL : 19.72
Total Revenue (TTM) VKTX : $0.00 MDGL : $958.40M
Gross Profit (TTM) VKTX : -$208.00K MDGL : $902.26M
EBITDA (TTM) VKTX : -$393.01M MDGL : -$300.10M

Returns By Period

In the year-to-date period, VKTX achieves a -6.31% return, which is significantly higher than MDGL's -9.02% return. Over the past 10 years, VKTX has underperformed MDGL with an annualized return of 36.57%, while MDGL has yielded a comparatively higher 50.73% annualized return.

VKTX

• 1D: 1.29%
• 1M: -1.14%
• YTD: -6.31%
• 6M: 20.42%
• 1Y: 37.85%
• 3Y*: 25.56%
• 5Y*: 39.32%
• 10Y*: 36.57%

MDGL

• 1D: 1.22%
• 1M: 21.63%
• YTD: -9.02%
• 6M: 17.97%
• 1Y: 63.54%
• 3Y*: 29.80%
• 5Y*: 34.90%
• 10Y*: 50.73%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VKTX vs. MDGL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VKTX

VKTX Risk / Return Rank: 59
VKTX Sharpe Ratio Rank: 58
VKTX Sortino Ratio Rank: 58
VKTX Omega Ratio Rank: 62
VKTX Calmar Ratio Rank: 59
VKTX Martin Ratio Rank: 59

MDGL

MDGL Risk / Return Rank: 78
MDGL Sharpe Ratio Rank: 82
MDGL Sortino Ratio Rank: 81
MDGL Omega Ratio Rank: 75
MDGL Calmar Ratio Rank: 77
MDGL Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VKTX vs. MDGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Madrigal Pharmaceuticals, Inc. (MDGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VKTX	MDGL	Difference
Sharpe ratio Return per unit of total volatility	0.48	1.40	-0.92
Sortino ratio Return per unit of downside risk	1.14	2.23	-1.09
Omega ratio Gain probability vs. loss probability	1.17	1.26	-0.09
Calmar ratio Return relative to maximum drawdown	0.81	2.04	-1.23
Martin ratio Return relative to average drawdown	1.79	4.47	-2.67
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VKTX vs. MDGL - Sharpe Ratio Comparison

The current VKTX Sharpe Ratio is 0.48, which is lower than the MDGL Sharpe Ratio of 1.40. The chart below compares the historical Sharpe Ratios of VKTX and MDGL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VKTX	MDGL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.48	1.40	-0.92
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.39	0.26	+0.13
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.37	0.43	-0.05
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.03	+0.10

Correlation

The correlation between VKTX and MDGL is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VKTX vs. MDGL - Dividend Comparison

Neither VKTX nor MDGL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VKTX vs. MDGL - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, smaller than the maximum MDGL drawdown of -98.40%. Use the drawdown chart below to compare losses from any high point for VKTX and MDGL.

Drawdown Indicators

	VKTX	MDGL	Difference
Max Drawdown Largest peak-to-trough decline	-90.41%	-98.40%	+7.99%
Max Drawdown (1Y) Largest decline over 1 year	-45.14%	-29.36%	-15.78%
Max Drawdown (5Y) Largest decline over 5 years	-78.86%	-61.41%	-17.45%
Max Drawdown (10Y) Largest decline over 10 years	-89.26%	-82.19%	-7.07%
Current Drawdown Current decline from peak	-65.12%	-12.11%	-53.01%
Average Drawdown Average peak-to-trough decline	-59.92%	-58.96%	-0.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.36%	13.43%	+6.93%

Volatility

VKTX vs. MDGL - Volatility Comparison

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 17.70% compared to Madrigal Pharmaceuticals, Inc. (MDGL) at 13.57%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than MDGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VKTX	MDGL	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.70%	13.57%	+4.13%
Volatility (6M) Calculated over the trailing 6-month period	45.64%	32.48%	+13.16%
Volatility (1Y) Calculated over the trailing 1-year period	78.45%	45.66%	+32.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	101.67%	133.38%	-31.71%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	98.98%	119.63%	-20.65%

Financials